On the stock market since 2018, it operates in the world of health and science. It has 154 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades below its recent peak — about 8% off the top. A pullback, not a collapse.
There is $421.4M in the vault; even if every debt were paid off, $417.2M would remain.
A loss of $126.4M against $0 in annual sales.
This stock swings about 2.6 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, CNST sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CNST is a high-risk stock — not yet profitable, and its future rides on its product catching on.